Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders

…, CL Szumlanski, RM Weinshilboum - Pharmacogenetics …, 1996 - journals.lww.com
… 893 randomly selected subjects showed that the frequency of the low activity allele was
0.46 (Spielman & Weinshilboum, 198l). Low COMT activity is also associated with enzyme …

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

RM Weinshilboum, SL Sladek - American journal of human …, 1980 - ncbi.nlm.nih.gov
WEINSHILBOUM RM: Human erythrocyte catechol-O-methyltransferase: correlation with
lung and kidney activity. Life Sci 22:625-630, 1978 25. REILLY DK, RIVERA-CALIMLIM L: Red …

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

…, J Hayden, S Lemler, RM Weinshilboum… - Journal of the …, 2005 - academic.oup.com
Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely
among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen …

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

…, JS Lilleyman, J Van Loon, RM Weinshilboum - The Lancet, 1990 - Elsevier
6-mercaptopurine (6-MP) can be inactivated by S-methylation, which is catalysed by
thiopurine methyltransferase (TPMT). An alternative metabolic route leads to the formation of …

Metabolomics: a global biochemical approach to drug response and disease

…, BS Kristal, RM Weinshilboum - Annu. Rev. Pharmacol …, 2008 - annualreviews.org
Metabolomics is the study of metabolism at the global level. This rapidly developing new
discipline has important potential implications for pharmacologic science. The concept that …

[HTML][HTML] Genomics and drug response

…, HL McLeod, RM Weinshilboum - New England Journal of …, 2011 - Mass Medical Soc
This article reviews recent pharmacogenetic and pharmacogenomic advances and
discusses how such advances are reflected in the labeling of drugs.

Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism

…, JA Van Loon, RM Weinshilboum - Clinical Pharmacology …, 1989 - Wiley Online Library
Azathioprine therapy can cause acute myelosuppression. Toxicity is in part caused by the
incorporation of azathioprine‐derived 6‐thioguanine nucleotides (6‐TGN) into …

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase

RM Weinshilboum, DM Otterness… - Annual review of …, 1999 - annualreviews.org
▪ Abstract Methyl conjugation is an important pathway in the biotransformation of many
exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase …

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

…, FJ Couch, WL Lingle, RM Weinshilboum… - Breast cancer research …, 2007 - Springer
Background Tamoxifen is biotransformed to the potent anti-estrogen, endoxifen, by the
cytochrome P450 (CYP) 2D6 enzyme. CYP2D6 genetic variation and inhibitors of the enzyme …

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

…, R Strick, MW Beckmann, H Koelbl, RM Weinshilboum… - Jama, 2009 - jamanetwork.com
Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone
receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and …